Guardant Health (NASDAQ:GH) Announces Quarterly Earnings Results

Guardant Health (NASDAQ:GH) issued its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.34, FiscalAI reports. The company had revenue of $334.98 million for the quarter, compared to analyst estimates of $314.23 million. During the same quarter last year, the business earned ($0.44) earnings per share. The company’s revenue was up 44.3% on a year-over-year basis.

Here are the key takeaways from Guardant Health’s conference call:

• Q2 revenue rose 44% year over year to $335 million, with broad-based growth across oncology, biopharma and data, and screening. Oncology testing volume increased 63% to approximately 104,000 tests, while Reveal volume more than doubled.
• Shield revenue increased to $53 million from $15 million a year earlier on approximately 66,000 tests. Inclusion in American Cancer Society guidelines and UnitedHealthcare coverage beginning August 1 expanded coverage to an estimated 70 million lives, or roughly 60% of the U.S. addressable market.
• The company raised 2026 revenue guidance to $1.34 billion-$1.36 billion, including Shield revenue of $218 million-$230 million and 270,000-285,000 Shield tests. Management also reaffirmed its goal of company-wide cash-flow breakeven by the end of 2027.
• Guardant received FDA approval for Guardant360 Liquid CDx and a higher-throughput, lower-cost Shield workflow. Guardant expects Shield cost per test to fall roughly 15% by the end of 2026 from approximately $410, with a longer-term target of $200 by 2028.
• The company is increasing investment to expand Shield laboratory capacity and commercial infrastructure, raising expected 2026 operating expenses to $1.08 billion-$1.10 billion and full-year free-cash-flow burn to $195 million-$205 million. Management said additional commercial payer wins are not included in current guidance, and reimbursement timing for Reveal remains uncertain.

Guardant Health Stock Up 5.7%

Shares of GH traded up $8.28 during mid-day trading on Thursday, hitting $152.35. 2,709,421 shares of the company’s stock were exchanged, compared to its average volume of 2,024,568. Guardant Health has a 52 week low of $40.35 and a 52 week high of $174.08. The stock’s 50-day simple moving average is $142.58 and its 200-day simple moving average is $113.03. The firm has a market cap of $20.20 billion, a price-to-earnings ratio of -44.94 and a beta of 1.59.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GH. Piper Sandler set a $127.00 target price on Guardant Health in a research note on Thursday, May 21st. Wolfe Research began coverage on Guardant Health in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Thursday, July 2nd. Royal Bank Of Canada started coverage on Guardant Health in a research report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective on the stock. Finally, Canaccord Genuity Group lifted their target price on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $160.04.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the completion of the sale, the director directly owned 11,048 shares in the company, valued at approximately $1,449,055.68. This represents a 15.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the sale, the chief executive officer directly owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 708,565 shares of company stock valued at $90,556,597 over the last ninety days. 5.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in shares of Guardant Health by 284.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 15,087 shares of the company’s stock valued at $785,000 after buying an additional 11,163 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Guardant Health by 5.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,546 shares of the company’s stock worth $669,000 after acquiring an additional 354 shares during the period. FIL Ltd boosted its position in shares of Guardant Health by 81.3% during the 4th quarter. FIL Ltd now owns 6,020 shares of the company’s stock worth $615,000 after acquiring an additional 2,699 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $575,000. Finally, Mariner LLC increased its stake in Guardant Health by 43.1% in the fourth quarter. Mariner LLC now owns 5,611 shares of the company’s stock valued at $572,000 after acquiring an additional 1,690 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, surpassing the $314.2 million consensus estimate. Oncology revenue increased 38% to $219.1 million, while oncology testing volume jumped 63% to approximately 104,000 tests. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The adjusted loss narrowed substantially. Guardant Health reported a second-quarter loss of $0.42 per share, better than the $0.76-per-share analyst estimate and improved from a $0.44 loss in the year-ago quarter. The earnings beat signals better operating leverage despite the company remaining unprofitable. Guardant Health Q2 Adjusted Loss Narrows, Revenue Rises
• Positive Sentiment: Guardant raised its fiscal 2026 revenue guidance to approximately $1.3 billion-$1.4 billion, compared with analyst expectations near $1.3 billion. The outlook increase reinforces confidence in demand for its precision-oncology testing products and was a key catalyst for the stock’s gain. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Neutral Sentiment: Management is scheduled to participate in investor conferences in August and September, providing potential opportunities to discuss growth, guidance and the path toward profitability. Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.